Polyneuron Pharmaceuticals, a BaseLaunch portfolio company, has concluded the extension of its Series A financing round. With further investment of 14 million francs, the startup has…
This second closing of CHF 4.7M is led by BioMedPartners AG and Altos Ventures AG, who are joining the previous investors Redalpine Venture Partners AG,…
Versameb also welcomes Dr. Klaas P. Zuideveld as Chief Development Officer. Prior to Versameb he was Vice President of Partnerships at Caris Life Sciences, and…
The orphan drug designation can only be granted for treatments on rare diseases to advance the developments of safe and effective therapies and the FDA…
PharmaBiome also welcomed two new board members with extensive biotech and entrepreneurial experience, all the way from founding to IPO. Dr. Thomas Meier joins PharmaBiome…
T3 Pharmaceuticals (T3 Pharma) has successfully closed a third financing round, raising over 25 million Swiss francs. According to a press release, the financing was co-led…
Congratulations to one of BaseLaunch’s portfolio companies, Polyneuron on their latest milestone: First clinical trial application approval. Wishing you great success with the studies later…
Anaveon, a Basel-based immuno-oncology biotech, has successfully concluded a Series A financing round led by Syncona, a UK Life Sciences fund, and joined by the…